Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467344 | 1.00 | MAPT (0.44) | MAPTALDH1A1HTTCES2CES1 | |
| SCHEMBL4453212 | 1.00 | MAPT (0.44) | MAPTALDH1A1HTTCES2CES1 | |
| SCHEMBL8770903 | 0.83 | L3MBTL1 (0.49) | MAPTALDH1A1HTTCES2CES1 | |
| SCHEMBL8770949 | 0.83 | CES2 (0.40) | MAPTALDH1A1HTTCES2CES1 | |
| SCHEMBL8770971 | 0.82 | HTT (0.59) | MAPTALDH1A1HTTRAB9ALMNA | |
| SCHEMBL8770924 | 0.81 | CES2 (0.39) | CES2CES1 | |
| SCHEMBL8771183 | 0.79 | L3MBTL1 (0.50) | ALDH1A1L3MBTL1 | |
| SCHEMBL8771019 | 0.79 | KCNA5 (0.38) | MAPTALDH1A1HTTL3MBTL1RAB9A | |
| SCHEMBL8770904 | 0.79 | L3MBTL1 (0.46) | MAPTALDH1A1L3MBTL1RAB9ALMNA | |
| SCHEMBL18640896 | 0.78 | ALDH1A1 (0.41) | MAPTALDH1A1HTTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | MAPT 4160/4885ALDH1A1 1977/4885HTT 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.